SCHEMBL14035880

SCHEMBL14035880

CCNc1ccc2nccnc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.50
ALDH1A1 P00352 7/20 0.50
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
NPC1 O15118 5/20 0.50
HPGD P15428 4/20 0.50
TP53 P04637 3/20 0.50
GAA P10253 3/20 0.50
CASP1 P29466 2/20 0.50
CASP7 P55210 2/20 0.50
HSD17B10 Q99714 2/20 0.50
MAPT P10636 7/20 0.49
KMT2A Q03164 7/20 0.49
MEN1 O00255 4/20 0.49
POLB P06746 3/20 0.49
ADRA2A P08913 2/20 0.47
ADRA2C P18825 2/20 0.47
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14609411 0.79 ALDH1A1 (0.49) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL1785420 0.79 ABL1 (0.51) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL12895806 0.78 NPC1 (0.60) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL20206686 0.78 ALDH1A1 (0.53) ALDH1A1NPC1CASP1CASP7KMT2A
SCHEMBL10309415 0.77 ADRA2A (0.52) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL13994276 0.76 KDM4E (0.58) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL18235952 0.76 KMT2A (0.44) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL20780035 0.75 ALDH1A1 (0.47) KDM4EALDH1A1RAB9ANPC1HPGD
SCHEMBL19966690 0.74 PTPN11 (0.60) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL29226534 0.74 KDM4E (0.55) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 KDM4E 3621/4885ALDH1A1 4081/4885RAB9A 2310/4885
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 KDM4E 638/4885ALDH1A1 4225/4885RAB9A 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.